Central sympatholytic drugs

Wanpen Vongpatanasin, Kazuomi Kario, Steven A. Atlas, Ronald G. Victor

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Key Points: Central sympatholytic drugs reduce blood pressure mainly by stimulating central α 2-adrenergic receptors in the brainstem centers, thereby reducing sympathetic nerve activity and neuronal release of norepinephrine to the heart and peripheral circulation. This class of drugs, however, is currently used mainly as fourth-line (or beyond) drug therapy for hypertension because of side effects of drowsiness, fatigue, and dry mouth. Rebound hypertension is also another major concern in certain drugs with a short half-life, particularly in patients who are nonadherent to the regimen. Therefore, their use on a "PRN" basis for treatment of blood pressure surge in the absence of symptoms or acute target complications should also be avoided.

Original languageEnglish (US)
Pages (from-to)658-661
Number of pages4
JournalJournal of clinical hypertension
Volume13
Issue number9
DOIs
StatePublished - Sep 2011

Fingerprint

Sympatholytics
Blood Pressure
Hypertension
Sleep Stages
Pharmaceutical Preparations
Adrenergic Receptors
Brain Stem
Fatigue
Half-Life
Mouth
Norepinephrine
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Central sympatholytic drugs. / Vongpatanasin, Wanpen; Kario, Kazuomi; Atlas, Steven A.; Victor, Ronald G.

In: Journal of clinical hypertension, Vol. 13, No. 9, 09.2011, p. 658-661.

Research output: Contribution to journalArticle

Vongpatanasin, Wanpen ; Kario, Kazuomi ; Atlas, Steven A. ; Victor, Ronald G. / Central sympatholytic drugs. In: Journal of clinical hypertension. 2011 ; Vol. 13, No. 9. pp. 658-661.
@article{3790ff637e7c4884a8332f6896d9c023,
title = "Central sympatholytic drugs",
abstract = "Key Points: Central sympatholytic drugs reduce blood pressure mainly by stimulating central α 2-adrenergic receptors in the brainstem centers, thereby reducing sympathetic nerve activity and neuronal release of norepinephrine to the heart and peripheral circulation. This class of drugs, however, is currently used mainly as fourth-line (or beyond) drug therapy for hypertension because of side effects of drowsiness, fatigue, and dry mouth. Rebound hypertension is also another major concern in certain drugs with a short half-life, particularly in patients who are nonadherent to the regimen. Therefore, their use on a {"}PRN{"} basis for treatment of blood pressure surge in the absence of symptoms or acute target complications should also be avoided.",
author = "Wanpen Vongpatanasin and Kazuomi Kario and Atlas, {Steven A.} and Victor, {Ronald G.}",
year = "2011",
month = "9",
doi = "10.1111/j.1751-7176.2011.00509.x",
language = "English (US)",
volume = "13",
pages = "658--661",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Central sympatholytic drugs

AU - Vongpatanasin, Wanpen

AU - Kario, Kazuomi

AU - Atlas, Steven A.

AU - Victor, Ronald G.

PY - 2011/9

Y1 - 2011/9

N2 - Key Points: Central sympatholytic drugs reduce blood pressure mainly by stimulating central α 2-adrenergic receptors in the brainstem centers, thereby reducing sympathetic nerve activity and neuronal release of norepinephrine to the heart and peripheral circulation. This class of drugs, however, is currently used mainly as fourth-line (or beyond) drug therapy for hypertension because of side effects of drowsiness, fatigue, and dry mouth. Rebound hypertension is also another major concern in certain drugs with a short half-life, particularly in patients who are nonadherent to the regimen. Therefore, their use on a "PRN" basis for treatment of blood pressure surge in the absence of symptoms or acute target complications should also be avoided.

AB - Key Points: Central sympatholytic drugs reduce blood pressure mainly by stimulating central α 2-adrenergic receptors in the brainstem centers, thereby reducing sympathetic nerve activity and neuronal release of norepinephrine to the heart and peripheral circulation. This class of drugs, however, is currently used mainly as fourth-line (or beyond) drug therapy for hypertension because of side effects of drowsiness, fatigue, and dry mouth. Rebound hypertension is also another major concern in certain drugs with a short half-life, particularly in patients who are nonadherent to the regimen. Therefore, their use on a "PRN" basis for treatment of blood pressure surge in the absence of symptoms or acute target complications should also be avoided.

UR - http://www.scopus.com/inward/record.url?scp=80052538033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052538033&partnerID=8YFLogxK

U2 - 10.1111/j.1751-7176.2011.00509.x

DO - 10.1111/j.1751-7176.2011.00509.x

M3 - Article

C2 - 21896146

AN - SCOPUS:80052538033

VL - 13

SP - 658

EP - 661

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 9

ER -